SCHEMBL20544757

SCHEMBL20544757

NCC(NC(=O)C1(NC(=O)O)CCN(c2ncnc3[nH]ccc23)CC1)c1ccc(Cl)cc1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 20/20 0.78
ROCK2 O75116 9/20 0.68
AKT2 P31751 7/20 0.68
AKT3 Q9Y243 7/20 0.68
KCNH2 Q12809 3/20 0.67
PRKD3 O94806 2/20 0.66
LATS1 O95835 2/20 0.66
PRKCB P05771 2/20 0.66
RET P07949 2/20 0.66
FGFR1 P11362 2/20 0.66
PRKCA P17252 2/20 0.66
PRKACA P17612 2/20 0.66
PRKACB P22694 2/20 0.66
GRK2 P25098 2/20 0.66
CLK1 P49759 2/20 0.66
LIMK1 P53667 2/20 0.66
LIMK2 P53671 2/20 0.66
PRKAG1 P54619 2/20 0.66
PRKCQ Q04759 2/20 0.66
PRKCD Q05655 2/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20544918 0.93 AKT1 (0.79) AKT1ROCK2AKT2AKT3KCNH2
SCHEMBL392547 0.93 AKT1 (0.78) AKT1ROCK2AKT2AKT3KCNH2
SCHEMBL20545432 0.92 AKT1 (0.79) AKT1ROCK2AKT2AKT3KCNH2
SCHEMBL15809880 0.92 AKT1 (0.79) AKT1ROCK2AKT2AKT3KCNH2
SCHEMBL28803704 0.92 AKT1 (0.79) AKT1ROCK2AKT2AKT3KCNH2
SCHEMBL20544988 0.92 AKT1 (0.80) AKT1ROCK2AKT2AKT3KCNH2
SCHEMBL20544778 0.90 AKT1 (0.79) AKT1ROCK2AKT2AKT3KCNH2
SCHEMBL20544493 0.90 AKT1 (0.80) AKT1ROCK2AKT2AKT3KCNH2
SCHEMBL20544952 0.90 AKT1 (0.80) AKT1ROCK2AKT2AKT3KCNH2
SCHEMBL20544830 0.89 AKT1 (0.80) AKT1ROCK2AKT2AKT3KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180312516-A1 Protein Kinase B Inhibitors ASTRAZENECA AB (SE) 2018-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180312516-A1 Protein Kinase B Inhibitors PRKAR2B, PRKCB, AKT1 AKT1 3/4885ROCK2 60/4885AKT2 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.